{"id":"aminosalicylate-sodium","rwe":[{"pmid":"39362239","year":"2024","title":"Nanoarchitectonics of tunable aminosalicylate sodium encapsulated gold nanoparticles enabling multi-faceted role as capping, reducing, stabilizing and colorimetric detection of metal ions.","finding":"","journal":"Nanotechnology","studyType":"Clinical Study"},{"pmid":"36986721","year":"2023","title":"Synthesis and Characterization of Linear Copolymers Based on Pharmaceutically Functionalized Monomeric Choline Ionic Liquid for Delivery of p-Aminosalicylate.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"30151969","year":"2019","title":"Hypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia.","finding":"","journal":"Internal medicine journal","studyType":"Clinical Study"},{"pmid":"27595122","year":"2016","title":"Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field.","finding":"","journal":"Journal of tuberculosis research","studyType":"Clinical Study"},{"pmid":"23112434","year":"2012","title":"Gynecomastia caused by ethionamide.","finding":"","journal":"Indian journal of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"aminosalicylic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tyrosine-protein phosphatase non-receptor type 1","category":"target"},{"label":"PTPN1","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"J04AA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Granule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Acute tuberculosis","category":"indication"},{"label":"Pulmonary tuberculosis","category":"indication"},{"label":"Consolidated Midland","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antitubercular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":662.712,"date":"","count":217,"signal":"Colitis ulcerative","source":"DrugCentral FAERS","actionTaken":"Reported 217 times (LLR=663)"},{"llr":392.103,"date":"","count":188,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 188 times (LLR=392)"},{"llr":316.903,"date":"","count":120,"signal":"Frequent bowel movements","source":"DrugCentral FAERS","actionTaken":"Reported 120 times (LLR=317)"},{"llr":245.803,"date":"","count":409,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 409 times (LLR=246)"},{"llr":214.398,"date":"","count":103,"signal":"Drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 103 times (LLR=214)"},{"llr":152.906,"date":"","count":101,"signal":"Haematochezia","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=153)"},{"llr":142.112,"date":"","count":82,"signal":"Hepatotoxicity","source":"DrugCentral FAERS","actionTaken":"Reported 82 times (LLR=142)"},{"llr":127.787,"date":"","count":86,"signal":"Rectal haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=128)"},{"llr":121.041,"date":"","count":124,"signal":"Intentional product use issue","source":"DrugCentral FAERS","actionTaken":"Reported 124 times (LLR=121)"},{"llr":99.455,"date":"","count":105,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 105 times (LLR=99)"},{"llr":95.983,"date":"","count":32,"signal":"Mucous stools","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=96)"},{"llr":84.887,"date":"","count":37,"signal":"Diarrhoea haemorrhagic","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=85)"},{"llr":76.383,"date":"","count":63,"signal":"Pancreatitis","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=76)"},{"llr":76.148,"date":"","count":42,"signal":"Polyneuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=76)"},{"llr":75.837,"date":"","count":154,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 154 times (LLR=76)"}],"commonSideEffects":[],"contraindications":["Acidosis","Anemia due to enzyme deficiency","Chronic heart failure","Cobalamin deficiency","Crystalluria","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Duodenal ulcer disease","Gastric ulcer","Goiter","Hypokalemia","Kidney disease","Peptic ulcer"],"specialPopulations":{"Pregnancy":"Pregnancy Category C: Aminosalicylic acid has been reported to produce occipital malformations in rats when given at doses within the human dose range. Although there probably is dose response, the frequency of abnormalities was comparable to controls at the highest level tested (two times the human dosage). When administered to rabbits at mg/kg, throughout all three trimesters, no teratologic or embryocidal effects were seen. Literature reports on aminosalicylic acid in pregnant women are lacking."}},"trials":[],"aliases":[],"company":"Consolidated Midland","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMINOSALICYLATE SODIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:09:49.275365+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:56.823392+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOSALICYLATE SODIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:57.724507+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dihydrofolate reductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:58.923615+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2096646/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:58.804535+00:00"}},"allNames":"apacil","offLabel":[],"synonyms":["aminosalicylic acid resin complex","potassium aminosalicylate","p-aminosalicylic acid","aminosalicylic acid","4-Aminosalicylic acid","4-Carboxy-3-hydroxyaniline","apacil","calcium aminosalicylate","sodium aminosalicylate","para-aminosalicylic acid","aminosalicylate potassium","aminosalicylate sodium","teebacin"],"timeline":[{"date":"1950-03-08","type":"positive","source":"DrugCentral","milestone":"FDA approval (Consolidated Midland)"}],"brandName":"Apacil","ecosystem":[{"indication":"Acute tuberculosis","otherDrugs":[{"name":"capreomycin","slug":"capreomycin","company":"Akorn"},{"name":"cycloserine","slug":"cycloserine","company":"Purdue Gmp"},{"name":"ethambutol","slug":"ethambutol","company":"Sti Pharma Llc"},{"name":"ethionamide","slug":"ethionamide","company":"Wyeth Pharms Inc"}],"globalPrevalence":1280000},{"indication":"Pulmonary tuberculosis","otherDrugs":[{"name":"bedaquiline","slug":"bedaquiline","company":"Janssen Therap"},{"name":"capreomycin","slug":"capreomycin","company":"Akorn"},{"name":"cycloserine","slug":"cycloserine","company":"Purdue Gmp"},{"name":"ethambutol","slug":"ethambutol","company":"Sti Pharma Llc"}],"globalPrevalence":1280000}],"mechanism":{"target":"Tyrosine-protein phosphatase non-receptor type 1","targets":[{"gene":"PTPN1","source":"DrugCentral","target":"Tyrosine-protein phosphatase non-receptor type 1","protein":"Tyrosine-protein phosphatase non-receptor type 1"},{"gene":"PTGS1","source":"DrugCentral","target":"Cyclooxygenase","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Cyclooxygenase","protein":"Prostaglandin G/H synthase 2"}],"modality":"Small Molecule","drugClass":"aminosalicylic acid","explanation":"","oneSentence":"","technicalDetail":"Apacil inhibits the activity of Tyrosine-protein phosphatase non-receptor type 1, a metallophosphoesterase involved in the dephosphorylation of substrates, thereby disrupting the bacterial cell wall synthesis and ultimately leading to the death of the bacteria."},"commercial":{"launchDate":"1950","_launchSource":"DrugCentral (FDA 1950-03-08, CONSOLIDATED MIDLAND)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2050","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMINOSALICYLATE%20SODIUM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOSALICYLATE SODIUM","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:45:44.170111","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:00.685499+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"aminosalicylate sodium","indications":{"approved":[{"name":"Acute tuberculosis","source":"DrugCentral","snomedId":25629007,"regulator":"FDA","eligibility":"patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to combination of resistance and/or intolerance","usPrevalence":null,"globalPrevalence":1280000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Pulmonary tuberculosis","source":"DrugCentral","snomedId":154283005,"regulator":"FDA","eligibility":"patients proven or suspected drug resistance, accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible","usPrevalence":null,"globalPrevalence":1280000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[{"name":"Crohn's disease","source":"DrugCentral","drugName":"AMINOSALICYLATE SODIUM","evidenceCount":22,"evidenceLevel":"moderate"},{"name":"Ulcerative colitis","source":"DrugCentral","drugName":"AMINOSALICYLATE SODIUM","evidenceCount":176,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT03830671","phase":"PHASE4","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2019-03-08","conditions":["Multi-drug Resistant Tuberculosis"],"enrollment":515,"completionDate":"2022-06-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Granule","formulations":[{"form":"GRANULE, DELAYED RELEASE","route":"ORAL","productName":"Paser"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000180192","MMSL":"10002","NDDF":"002845","UNII":"5B2658E0N2","VUID":"4018852","CHEBI":"CHEBI:27565","VANDF":"4018852","RXNORM":"7833","UMLSCUI":"C0030125","chemblId":"CHEMBL2096646","ChEMBL_ID":"CHEMBL1169","KEGG_DRUG":"D00162","DRUGBANK_ID":"DB00233","PDB_CHEM_ID":"BHA","PUBCHEM_CID":"4649","SNOMEDCT_US":"20231007","SECONDARY_CAS_RN":"133-09-5","MESH_DESCRIPTOR_UI":"D010131"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1950-","companyName":"Consolidated Midland","relationship":"Original Developer"}],"publicationCount":8,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J04AA01","allCodes":["J04AA01","J04AA02","J04AA03"]},"biosimilarFilings":[],"originalDeveloper":"Consolidated Midland","recentPublications":[{"date":"2024 Oct 16","pmid":"39362239","title":"Nanoarchitectonics of tunable aminosalicylate sodium encapsulated gold nanoparticles enabling multi-faceted role as capping, reducing, stabilizing and colorimetric detection of metal ions.","journal":"Nanotechnology"},{"date":"2023 Mar 7","pmid":"36986721","title":"Synthesis and Characterization of Linear Copolymers Based on Pharmaceutically Functionalized Monomeric Choline Ionic Liquid for Delivery of p-Aminosalicylate.","journal":"Pharmaceutics"},{"date":"2019 Mar","pmid":"30151969","title":"Hypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia.","journal":"Internal medicine journal"},{"date":"2016 Sep","pmid":"27595122","title":"Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field.","journal":"Journal of tuberculosis research"},{"date":"2012 Sep-Oct","pmid":"23112434","title":"Gynecomastia caused by ethionamide.","journal":"Indian journal of pharmacology"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Century Pharms","Hexcel","Lannett"],"status":"approved","companyName":"Consolidated Midland","companyId":"consolidated-midland","modality":"Small molecule","firstApprovalDate":"1950","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:00.685499+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}